Drug Profile
Research programme: antivirals - Arisyn Therapeutics
Alternative Names: ATI-0409; ATI-0607; ATI-0655; ATI-0810; ATI-5488; PG 301209; PG-301995Latest Information Update: 12 May 2015
Price :
$50
*
At a glance
- Originator Procter & Gamble
- Developer Arisyn Therapeutics
- Class Small molecules
- Mechanism of Action Hepatitis B virus replication inhibitors; Hepatitis C virus replication inhibitors; HIV replication inhibitors; RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis B; Hepatitis C; Herpes simplex virus infections; HIV infections; Influenza virus infections
Most Recent Events
- 15 Sep 2009 Pharmacodynamics data from in vitro studies in Hepatitis C presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)
- 14 May 2009 Pharmacodynamics data from a preclinical trial of ATI 0810 in Hepatitis C released by ImQuest and Arisyn
- 24 Nov 2008 Compounds from this programme are available for licensing (http://www.arisyn.com)